Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessment of first-touch skills in robotic surgical training using hi-Sim and the hinotori surgical robot system among surgeons and novices.
Urade T, Yamasaki N, Uemura M, Hirata J, Okamura Y, Mitani Y, Hattori T, Nanchi K, Ozawa S, Chihara Y, Chinzei K, Fujisawa M, Fukumoto T. Urade T, et al. Among authors: chihara y. Langenbecks Arch Surg. 2024 Nov 1;409(1):332. doi: 10.1007/s00423-024-03514-6. Langenbecks Arch Surg. 2024. PMID: 39482467 Free PMC article.
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with NSCLC with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs Chemoimmunotherapy: A Multicenter, Retrospective Study.
Nishioka N, Hata T, Yamada T, Goto Y, Amano A, Negi Y, Watanabe S, Furuya N, Oba T, Ikoma T, Nakao A, Tanimura K, Taniguchi H, Yoshimura A, Fukui T, Murata D, Kaira K, Shiotsu S, Hibino M, Okada A, Chihara Y, Kawachi H, Kijima T, Takayama K. Nishioka N, et al. Among authors: chihara y. Cancer Res Treat. 2024 Oct 25. doi: 10.4143/crt.2024.748. Online ahead of print. Cancer Res Treat. 2024. PMID: 39482992 Free article.
Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01.
Hibino M, Imamura Y, Shimoyama R, Fukui T, Fukai R, Iwase A, Tamura Y, Chihara Y, Okabe T, Uryu K, Okuda T, Taguri M, Minami H. Hibino M, et al. Among authors: chihara y. Target Oncol. 2024 Nov;19(6):925-939. doi: 10.1007/s11523-024-01094-5. Epub 2024 Sep 20. Target Oncol. 2024. PMID: 39302602 Free PMC article.
The Significance of Longitudinal Psoas Muscle Loss in Predicting the Maintenance Efficacy of Durvalumab Treatment Following Concurrent Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer: A Retrospective Study.
Kuno H, Nishioka N, Yamada T, Kunimatsu Y, Yoshimura A, Hirai S, Futamura S, Masui T, Egami M, Chihara Y, Takayama K. Kuno H, et al. Among authors: chihara y. Cancers (Basel). 2024 Aug 30;16(17):3037. doi: 10.3390/cancers16173037. Cancers (Basel). 2024. PMID: 39272894 Free PMC article.
CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study.
Kataoka N, Katayama Y, Yamada T, Morimoto K, Takeda T, Okada A, Shiotsu S, Chihara Y, Hiranuma O, Yamada T, Ota T, Harada T, Hasegawa I, Nishioka N, Iwasaku M, Tokuda S, Takayama K. Kataoka N, et al. Among authors: chihara y. Transl Lung Cancer Res. 2024 Aug 31;13(8):1929-1937. doi: 10.21037/tlcr-24-190. Epub 2024 Aug 20. Transl Lung Cancer Res. 2024. PMID: 39263030 Free PMC article.
247 results